Clinical Focus

  • Interventional Pulmonology
  • Pulmonary Medicine
  • Pleural Disease
  • Lung Cancer
  • Critical Care
  • Internal Medicine

Academic Appointments

Professional Education

  • Board Certification, American Association of Bronchology and Interventional Pulmonology, Interventional Pulmonology (2021)
  • Board Certification: American Board of Internal Medicine, Critical Care Medicine (2019)
  • Board Certification: American Board of Internal Medicine, Pulmonary Disease (2018)
  • Board Certification: American Board of Internal Medicine, Internal Medicine (2016)
  • Fellowship, Cleveland Clinic, Interventional Pulmonary Medicine (2020)
  • Fellowship, Stanford University, Pulmonary & Critical Care Medicine (2019)
  • Residency, Stanford University, Internal Medicine (2016)
  • Medical Education, Albert Einstein College of Medicine, Doctor of Medicine (M.D.) (2013)


All Publications

  • "I Now Walk Into the Wild": Atelectasis During Peripheral Bronchoscopy Under General Anesthesia. Chest Shaller, B. D., Almeida, F. A. 2020; 158 (6): 2268–69

    View details for DOI 10.1016/j.chest.2020.07.029

    View details for PubMedID 33280747

  • Atypical Blastomycosis Masquerading as Lofgren Syndrome. American journal of respiratory and critical care medicine Shaller, B. D., Chen, S. B., Ho, D. Y., Yu, D. H. 2020

    View details for DOI 10.1164/rccm.201911-2158IM

    View details for PubMedID 32516540

  • A generalizable 29-mRNA neural-network classifier for acute bacterial and viral infections. Nature communications Mayhew, M. B., Buturovic, L., Luethy, R., Midic, U., Moore, A. R., Roque, J. A., Shaller, B. D., Asuni, T., Rawling, D., Remmel, M., Choi, K., Wacker, J., Khatri, P., Rogers, A. J., Sweeney, T. E. 2020; 11 (1): 1177


    Improved identification of bacterial and viral infections would reduce morbidity from sepsis, reduce antibiotic overuse, and lower healthcare costs. Here, we develop a generalizable host-gene-expression-based classifier for acute bacterial and viral infections. We use training data (N=1069) from 18 retrospective transcriptomic studies. Using only 29 preselected host mRNAs, we train a neural-network classifier with a bacterial-vs-other area under the receiver-operating characteristic curve (AUROC) 0.92 (95% CI 0.90-0.93) and a viral-vs-other AUROC 0.92 (95% CI 0.90-0.93). We then apply this classifier, inflammatix-bacterial-viral-noninfected-version 1(IMX-BVN-1), without retraining, to an independent cohort (N=163). In this cohort, IMX-BVN-1 AUROCs are: bacterial-vs.-other 0.86 (95% CI 0.77-0.93), and viral-vs.-other 0.85 (95% CI 0.76-0.93). In patients enrolled within 36h of hospital admission (N=70), IMX-BVN-1 AUROCs are: bacterial-vs.-other 0.92 (95% CI 0.83-0.99), and viral-vs.-other 0.91 (95% CI 0.82-0.98). With further study, IMX-BVN-1 could provide a tool for assessing patients with suspected infection and sepsis at hospital admission.

    View details for DOI 10.1038/s41467-020-14975-w

    View details for PubMedID 32132525

  • What is the value of electromagnetic navigation in lung cancer and to what extent does it require improvement? Expert review of respiratory medicine Shaller, B. D., Gildea, T. R. 2020; 14 (7): 655–69


    Lung nodules are being identified with increasing frequency. With this growing burden of nodules comes a growing need for diagnostic technologies extending beyond the current reach of conventional bronchoscopy. One such method for diagnosing peripheral lung lesions is electromagnetic navigational bronchoscopy (ENB), which comprises a set of tools designed to aid the bronchoscopist in identifying, accessing, and sampling peripheral lung lesions under virtual guidance.Herein we present an in-depth review of ENB, including commercially available electromagnetic navigation platforms, factors influencing diagnostic yield, adjunctive imaging and biopsy tools, potential risks, cost, technical shortcomings, and competing technologies. A review of the scientific literature was conducted primarily through PubMed, ScienceDirect, and Google Scholar, and pertinent publications and abstracts from the inception of electromagnetic navigation through early 2020 were considered. We also share our perspective on the future of ENB from both a diagnostic and a therapeutic standpoint.ENB is currently a leading tool in the diagnostic evaluation of peripheral lung lesions. The future of ENB rests not only on its potential to expand into the therapeutic realm but also on its ability to keep pace with competing diagnostic and therapeutic technologies.

    View details for DOI 10.1080/17476348.2020.1748012

    View details for PubMedID 32216487

Latest information on COVID-19